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We introduce the use of a peptide composition lookup table indexed by residual mass and
number of amino acids for de novo sequencing of polypeptides. Polypeptides of 1600 Daltons
(Da) or more can be sequenced effectively through exhaustive compositional analysis of
MS/MS spectra obtained by unimolecular decomposition (without CID) in a MALDI TOF/
TOF despite a fragment mass accuracy of 50 mDa. Peaks are referenced against the lookup
table to obtain a complete profile of amino acid combinations, and combinations are assembled
into series of increasing length. Concatenating the differences between successive entries in
compositional series yields peptide sequences that can be scored and ranked according to
signal intensity. While the current work involves measurements acquired on MALDI TOF-
TOF, such general treatment of the data anticipates extension to other types of mass
analyzers. (J Am Soc Mass Spectrom 2006, 17, 1041–1049) © 2006 American Society for Mass
SpectrometryWhile protein identification most commonlyrelies on established database searching rou-tines [1–4], examples persist of demand for
fast and reliable peptide sequencing due to incomplete
or inadequate databases [5–9]. De novo peptide se-
quencing algorithms also abound [5, 10–17], but objec-
tive assessments of de novo peptide sequencing capa-
bilities with unknowns [18] indicate that much work
remains.
One recently described de novo sequencing method
has taken an approach that is wholly different from
others reported to date [15]. It employs logical process-
ing of all amino acid combinations from the parent ion
and prominent fragments to obtain several relevant
amino acid combinations, which are permuted into
sequences; the presence of other peaks guides the
selection of a final sequence. This method presents a
straightforward and desirable means for sequence val-
idation and for obtaining sequences of peptides inde-
pendently of how well they fragment. However, the
resolution and mass accuracy specifications for this
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characteristics of Fourier transform mass spectrometry
(FTMS).
The use of exhaustive peptide-relevant elemental
combinations, as Spengler [15] has done, represents one
particular understated advantage: it allows the inherent
distinction of the correct ion type for use in sequence
analysis. Thus, the generation of a sequence de novo is
not misguided by neutral losses and/or high-energy
fragmentation (x-, w-, c-, or d-) ions. Nearly all previ-
ously published de novo peptide sequencing methods
[10–16] incorporate neutral loss, high-energy fragmen-
tation, and a-type ions into the scoring and selection of
the ultimate sequence. Extensive variability in any
solution generated by them appears to stem from the
implementation of this feature; a robust comparison of
the advantages and shortcomings in these various scor-
ing schemes, involving fragmentation simulations [16,
19], arbitrary values [13, 15], empirical assignment
functions [14], or a combination, seems a worthwhile
venture, especially in view of peptide and instrumental
variability. While the importance of these nonsequence
ions to the reinforcement of sequence validation cannot
be underestimated, their highly variable frequency and
intensity present significant obstacles to their accurate
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able sequence shunting observed in algorithms that rely
on neutral loss and high-energy fragmentation ions
excessively.
Tandem TOF spectra obtained via unimolecular de-
compositions, i.e., without CID, contain more exten-
sive—generally complete—fragmentations. This supe-
rior fragmentation carries a penalty of somewhat
decreased mass accuracy in the fragment ions, com-
pared with FTMS spectra, as a consequence of energy
distributions within the analyzers being only partially
resolved; in this paper the mass accuracy of TOF-TOF
fragment spectra is assumed to be 50 mDa. While it is
unclear what would be the effect of such large mass
errors on the only published use of amino acid combi-
nations for de novo sequencing [15] , previous strategies
for sequencing with TOF-TOF data [5, 14] do not fully
exploit the potential of using mass accuracy data. This
may partially explain some of their erroneous results.
The approach described here utilizes a reasonable mass
accuracy for unimolecular decomposition fragments
and the straightforward compositional analysis allowed
by LIPCUT (length incremented peptide composition
lookup table) to gain highly reliable sequence informa-
tion from TOF-TOF data.
Experimental
Materials
Acetonitrile (ACN HPLC grade), TFA, reagent grade
dihydrogen ammonium phosphate (AmPhos), and
a-cyano-4-hydroxycinnamic acid (HCCA) were ob-
tained from Aldrich Chemical Co. (Milwaukee, WI);
HCCA was recrystallized before use. The b-galactosi-
dase digest and three peptides des-Arg1-Bradykinen,
angiotensin 1, and glu-fibrinogen peptides were ob-
tained from Applied Biosystems Inc. (Framingham,
MA); the three individual peptides are part of a mixture
of calibration standards, ABI4700 Calibration Mixture.
BSA was obtained from Sigma Chemical Co. (St. Louis,
MO), digested in solution under standard conditions
using sequencing grade modified porcine trypsin (Pro-
mega, Madison, WI). Water for general use was gener-
ated using a Hydro Services (Rockville, MD) deionizing
purification system.
Mass Spectrometry
Samples were formed by applying 0.3 uL of one of the
three peptide mixtures to an Applied Biosystems 192
well OptiPlate disposable sample stage; peptide con-
centrations were all adjusted to be 1 pmol/uL. An equal
volume of matrix solution was applied to each peptide
mixture before it had dried; the matrix solution was 5
mg/mL HCCA dissolved in 900 uL of 1:1::0.1% TFA:
ACN to which 100 uL of 0.1M solution of AmPhos was
added.MALDI MS and MS/MS spectra were obtained in asemi-automated fashion using an Applied Biosystems
4700 Proteomics Analyzer with TOF/TOF ion optics
(Applied Biosystems, Inc); in MS/MS mode the instru-
ment was always operated with the collision gas off. A
diode pumped Nd:YAG laser with a 600 ps pulse length
was used. The instrument has been described in detail
elsewhere [5, 20]. The instrument was controlled by ABI
4700 Series Explorer (version 3.0). All calibrations were
performed only after allowing instrument voltages to
stabilize for at least 60 min in the operation mode. The
sample plate calibration file was updated for each plate
using five spots of the ABI4700 calibration mixture. MS
mode default calibration was updated daily using a
calibration mixture spot in the center of the plate.
MS/MS default calibration was updated based on suc-
cessfully performing an internal calibration using the
y-series fragment ions of Glu-fibrinogen peptide, m/z
1570.677; criteria for successful MS/MS internal calibra-
tion included maximum outlier error no greater than
0.035 Da and that at least 12 fragment ion masses were
found.
Spectra were obtained for each sample using 500
laser shots in MS mode and 3500 shots in MS/MS; up to
five MS/MS spectra were obtained from each spot.
Tandem mass acquired by accelerating precursor ions
to 8 keV, selecting them with the timing gate (TIS) set to
a resolution of 50 and then accelerating fragment ions to
14 keV before entering the reflector.
Peptide Composition Lookup Table
The basis of the entire approach taken here is the
generation of the LIPCUT database that contains all
peptide residue mass combinations for masses less than
2 kDa. It should be noted at this point that the LIPCUT
database consists of a nonredundant listing of residue
masses, i.e., peptide masses absent a mole of water; as
will be shown below, this is a more general approach
than simply listing peptide masses because of the
greater flexibility provided in generating sequences.
The table was generated by two independent methods,
which were then used for cross validation: simple
recursion and elemental combination. The isobars
leucine and isoleucine were treated as the same residue
and given the symbol X for all calculations. Recursion
Table 1. Parameters for LIPCUT generation
Ratio
Min
value
Min
value AAs
Max
value
Max
value AAs
C/C 1.0 All 1.0 All
H/C .91 W 2.0 K,R
N/C .11 Y,F .67 R
O/C .09 W .75 D
S/C 0 All except M,C .33 C
The minimum and maximum values for the ratios of C,H,N,O and S
against C for amino acid residues as well as the amino acid where these
ratios are foundon the 19 residues was performed using alphabetically
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using elemental combination, minimum and maximum
ratios relative to carbon were calculated for the five
elements found in peptides, C, H, N, O, and S. Table 1
shows the bounds for ratios. The monoisotopic mass of
a peptide is the sum of contributions from individual
elements:
massMCNCMHNHMNNNMONOMSNS (1)
where NC, NH, NN, NO, and NS are the respective
numbers of moles of C,H,N,O, and S, and MC, MH, MN,
MO, and MS are monoisotopic masses for C, H, N, O,
and S. Using H and the maximum H/C ratio as an
example in eq 2, the maximum moles of hydrogen for
any mass can be expressed in terms of the minimum
moles of carbon.
Nmax HNmin CRmax H/C (2)
Thus, the minimum number of carbons in a peptide for
a given mass is known by a simple linear equation
utilizing the maximum element versus carbon ratios in
eq 3.
Nmin C
mass
MCMHRmax H/CMNRmax N⁄C
MORmax O⁄CMSRmax S⁄C
(3)
The maximum number of carbons can be obtained by
substituting the minimum element versus carbon
ratios from Table 1 into eq 3. The same method can be
used for substituting the minimum and maximum
amounts of any element in a peptide for a given mass.
Determination of the amino acid combinations within
those elemental bounds and within a specified mass
window yields the amino acid combinations for the
mass.
Several indexing schemes and formats were investi-
gated with the goal of optimizing computational speed
for high throughput lookup. The LIPCUT used in this
paper is formatted as a Berkeley database [21]. The
primary key of the database is the number of amino
acids in the combination, and the single secondary key
is the sum of amino acid residue monoisotopic mass of
that combination carried to five decimal places. This
configuration was chosen because it balances the de-
mands for functionality as well as for size and portabil-
ity. Sorting and indexing the LIPCUT two ways allows
for a more efficient processing of information: the mass
increments allow for easy lookup with few compari-
sons, and the length increments allow for a grouping of
compositions in a way that economizes the linking of
series. Generation of LIPCUT, which only needs to be
done once, utilized the high-performance computa-
tional capabilities of the Biowulf PC/Linux cluster at
the National Institutes of Health, Bethesda, MD [22].
LIPCUT is available upon request.Development of a Sequence
Scheme 1 is a flow chart of the process for develop-
ment of a peptide sequence from an MS/MS spec-
trum. The first two steps are input functions that
could be tailored to any type of fragmentation spec-
tra; they are used to format the spectral data in a
manner that an algorithm can employ LIPCUT. The
final step is an output function that takes the results
of the algorithm and arranges them in an interpret-
able fashion. The overall package of programs has
been named MAARIAN (mass amino acid analysis by
residue index for association of nodes).
Peak Processing
The ABI 4700 Series Explorer (version 3.0) software
reports peak intensity as an integer multiple of signal
versus noise (S/N). For each spectrum in these ex-
periments, a peak list containing all peaks above a
S/N value of 3 was exported as a flat text file from the
Explorer software. We found it necessary to imple-
ment a peak filtering step to reduce excessive noise in
spectra with overall low intensities. A typical signal
histogram for the spectra used in this work is shown
in Figure 1. Peaks having S/N values with frequency
greater than an arbitrary value of 10 were classified
as intense. Low S/N and high-frequency signals
increase processing time [12] and generally present
no helpful information for estimating sequence; they
are filtered from a dataset for compositional analysis
but saved for the use of elucidating other fragments.
Due to the irregularity of noise distributions, it was
found that signal filtration based solely on either
frequency or S/N occasionally removes useful signal.
To preserve the fidelity of the peak list, our approach
Peak Processing
Spectrum Encoding
Sequencing
Algorithms
Results Decoding
LIPCUT
Data Set
Spectrum Peaks
Scheme 1erred on the side of less filtration rather than more; all
1044 OLSON ET AL. J Am Soc Mass Spectrom 2006, 17, 1041–1049peaks with a S/N greater than that having a fre-
quency of 10 or less were used for analysis. Intensities
of the filtered peaks were normalized to 1000 to
clarify scoring.
Currently the S/N filter considers only monoiso-
topic peaks. Other components of the isotope cluster
or any potential multiply charged ions, unlikely as
they might be in MALDI, are ignored. Extension of
this method to spectra generated by electrospray
ionization will require an additional peak processing
step to detect and deconvolute isotope clusters for
multiply charged ions.
Encoding the Spectrum
Since LIPCUT is based on peptide residue masses,
filtered spectra must be encoded appropriately to make
use of them. At this point in the development of our
approach, we treat all ions of a spectrum that pass the
Figure 1. (a) S/N histogram for all the signal in a spectrum of the
tryptic BSA fragment 42-51 (XVNEXTEFAK). (b) Enlarged portion
of the histogram; the horizontal line shows the arbitrary frequency
cutoff; the minimum S/N with a frequency 10 occurs at S/N 21,
so every peak with a S/N  21 (shown by the vertical line) is
considered during compositional analysisfilter as either y- or b-series ions recognizing that thisassumptions is not likely to be entirely accurate. The
encoding step treats each filtered peak both as a y- or
b-series ion, by subtracting the monoisotopic molecular
weight of H3O (19.01839 Da) from the measured mass in
the first case, and by subtracting the mass of a hydrogen
atom (1.007825 Da) in the second. It is these “residual
mass ions” that are referenced against LIPCUT in
subsequent calculations. With this approach each ion in
a spectrum will possibly, depending on its exact mass,
lead to two different amino acid compositions, but care
has been taken to include any given ion only once in a
sequence, preferentially as a member of a y-series. The
basis of the algorithms is that compositions inconsistent
with a complete sequence are simply eliminated from
further consideration. Peaks representing non-y or
non-b ions simply go unassigned in the spectrum.
De Novo Peptide Sequencing Algorithm
A family of five algorithms that function either by chain
extension or matching through some criterion of the
spectrum and database have been developed to exploit
the properties of LIPCUT. All of them are written as
open source code and will be available upon request
following the publication of a paper describing them in
detail, along with a number of performance bench-
marks [23]. The results presented herein have used one
of the extension algorithms that assembles composi-
tional series of increasing length from the exhaustive
lists of ionic compositions found in the spectrum after
referring to LIPCUT. It is similar to the stepwise ap-
proach [5] used earlier, but modified to operate with the
exact masses and large numbers of amino acid compo-
sitions encountered. Additionally, contrary to previous
uses of this approach, no initial assumptions are re-
quired before the sequence is generated. Growing com-
positional series need not reach the parent ion residual
mass due to b complementation of y ions and vice
versa. The algorithm can handle extensions to accom-
modate any number of missed fragmentations, but for
this initial work, a single missed fragmentation (the
addition of two amino acids) has been taken as the
acceptable limit.
Decoding Compositions
The aforementioned sequencing algorithms generate
series of y- and b-type amino acid compositions from
which complete amino acid sequences can be derived.
In the simplest case, the entire sequence can be derived
from a single ion type, and the series consists of amino
acid compositions of ascending length. Decoding this
case involves concatenating the amino acid differences
between the compositions of ascending members of the
series and arranging the differences in the appropriate
order (N- to C-terminal for b-series, and C- to N-
terminal for y-series). While the y-series in unimolecu-
lar decompositions can be sufficient for the deduction of
VLQR
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with either y- or b-compositions.
Sequence Scoring
The score for the sequence is the sum of intensities for
all the peaks, which have amino acid compositions that
support the sequence. Attempts were made to incorpo-
rate a calculation of mass error into the sequence score,
but no improvement was realized.
Results and Discussion
The results for determining the sequence of 22 standard
peptides from three different sources are summarized
in Table 2. Of these 22, seven are determined correctly
with no ambiguities other than being unable to resolve
the near isobars of K and Q. A significant aspect of these
results is that the b-galactosidase peptide at m/z
1446.841 had a C-terminal portion consistent with a
portion of the protein’s amino terminal, but the se-
quence found was longer than that published for this
peptide. We speculate that this recombinant form of the
protein was synthesized by cloning a vector that em-
ployed a variant amino terminal. Of the other 15
peptides, 11 were determined to within a single missed
Table 2. Results Summary
Precursor Expected
b-Galactosidase
232–238 900.385 FNDDFSR
433–440 989.488 WLPAMSER
954–962 1083.522 GDFQFNISR
802–810 1099.554 IDPNAWVER
623–631 1265.642 HQQQFFQFR
944–953 1299.623 ELNYGPHKW
507–518 1341.669 VDEDQPFPA
168–169 1394.732 LPSEFDLSA
16–27 1428.687 DWENPGVT
N-Terminal 1446.841 . . .LAVVL
963–974 1507.696 YSQQQLME
BSA
161–167 927.494 YLYEIAR
66–75 1163.631 LVNELTEFA
25–34 1193.603 DTHKSEIAH
35–44 1249.622 FKDLGEEHF
402–412 1305.717 HLVDEPQNL
437–451 1639.938 KVPQVSTPL
Misc Peptides
des-Arg1-Bradykinin 904.460 PPGFSPFR
Angiotensin 1 1296.685 DRVYIHPFHL
Glu-Fibrino peptide 1570.677 EGVNDNEEG
Synthetic 1 1018.408 SAQEPSQGN
Synthetic 2 1166.416 DNDEEEGPF
aIn this table X represents the isobaric amino acids Ile and Leu.
bMissed fragmentations are shown within parentheses and near-isoba
braces.
cAverage time using 2.5 GHz Power Mac G5.
dThe published N-terminal sequence for this peptide is: MVASSLALAVfragmentation, shown by two residues within parenthe-ses, or two isobaric pairs within parentheses, one of
which is correct, within square brackets. Of this set of
15, 11 were clarified by the use of internal fragment ions
to yield the correct sequences as discussed below. Only
one peptide, synthetic 1, a nontryptic-like synthetic
molecule, yielded results that differed appreciably from
the correct sequence at the C-terminus; the incorrect
residues are shown in bold italic within braces; the
portion of the sequence that was correct was ranked
second, the only instance of missing a correct determi-
nation.
The execution time to produce these sequences is
given in the last column of the table. All calculations
were performed using a 2.5 GHz Power Mac G5 run-
ning OS 10.4.5 and Perl 5.8.4. These times were achieved
by using the minimal levels of the filtering described
above that gave any results at all. That is, in some of the
spectra, the distribution of S/N frequencies was such
that a more relaxed value of the filter was required to
have sufficient peaks to give any results. Typically, this
involved starting with a value of 10, as shown in Figure
1, and the increasing the minimum frequency to get a
clear result. As the minimum frequency was increased,
the execution times increased, and at least part of the
slower execution times in Table 2 are a result of this.
The overall average execution time was 2.9 s.
MAARIAN-LIPCUT seqa,b
Execution time
(sec)c
(FN)DDFSR 0.22
WXPAMSER 0.26
[(DG)|(AT)]FKFNXSR 3.09
[(DX)|(EV)]PNAWVER 3.27
HQQQFFKFR 0.64
EXNYGPHKWR 1.43
VDED[K|Q]PFPAV(KP) 5.60
(PX)SEFDXSAFXR 0.38
R (DW)ENPGVTKXNR 1.45
(MT)XTDSXAVVXKR 0.64
YSQQ(KX)METSHR 0.22
YXYEXAR 8.82
(VX)NEXTEFAK 1.29
DTHKSEXAHR 0.46
FKDXGEEH(FK) 3.19
HXVDEP[K|Q]NX(KX) 0.78
R KVPQVS(PT)LVEVSR 0.46
PPGFSPFR 1.91
DRVYXHPF(HX) 16.57
AR [(EG)|(AD)]VNDNEEGFFSAR 0.87
SAQEPS {EDR} 6.84
DNDEEEGPFD 5.02
ss alternatives within square brackets. Incorrect sequences are withinseq
R
VPK
FLR
QLN
QRd
TSHR
K
R
K
IK
VEVS
FFS
T
D
ric maWe were able to resolve the missing fragmentation
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ments within the original spectra; at this stage of our
development this was done manually. For example, the
near isobaric missed fragment of b-galactosidase 954-
962 (m/z 1083.522) was shown to have the sequence
GDFQ.. by the presence of an internal fragment, m/z
391.16 corresponding to . . .DFQ. . .; the N-terminal am-
biguity of m/z 1446.841 b-galactosidase peptide was
resolved by the internal fragment, m/z 518.25, corre-
sponding to the sequence . . .TXTDS. . ., thereby placing
the methionine residue at the amino terminus as ex-
pected, as illustrated in Figure 2. The C-terminal ambi-
guities of both the 402-412 peptide of BSA and angio-
tensin I were resolved in a similar fashion, i.e., the m/z
Figure 2. Fragmentation (MSMS) spectrum of b-galactosidase
peptide MTLTDSLAVVLKR showing y-series ions. Inset shows
the internal ion TLTDS that resolves the unfragmented N-
terminal sequence ambiguity.
Figure 3. Fragmentation (MSMS) spectrum of synthetic peptide
2, DNDEEEGPFD showing an incomplete y-series, but a complete
sequence due to the presence of complimentary b-series ions.285.14 ion corresponding to HF in the case of the BSApeptide and the two ions, m/z 519.25 and 632.33, corre-
sponding to HPFH and XHPFH for angiotensin I. Note
also that two of the three nontryptic peptides studied,
angiotensin I and DNDEEEGPFD (MH  1166), were
sequenced correctly. The annotated spectrum for the
nontryptic DNDEEEGPFD is shown in Figure 3 and
illustrates an extensive b-series that compensates for an
incomplete set of y-series fragments. A similar process
was followed for the incomplete fragmentations shown
in Table 2 and was successful in all but three cases. The
spectrum of the b-galactosidase peptide 232-238, m/z
900.385, had overall too low an intensity to identify any
internal fragments. In the case of the remaining two
peptides, b-galactosidase 168-189, m/z 1394.732, and
BSA 66-75, m/z 1163.631, the internal fragments in the
spectra did not yield unambiguous results.
As shown above, the 36.4 mDa difference between
lysine (K) and glutamine (Q) cannot be resolved unam-
biguously in every case. On the other hand, our results
indicate that the use of independent compositional
analysis for each peak tends to shift the sequence score
in favor of the correct sequence, as shown by the
unambiguous assignment of a Q or K residue in 13 of
the 21 possible instances in this set of 20 peptides. This
is also apparent from the correct assignment of the
C-terminal lysine in the tryptic fragments. As our
algorithm makes no assumptions about the origin of
peptides, the possibility exists of obtaining an incorrect
sequence ending in glutamine, but we do not
find this. For example, in the BSA fragment 66-75
(XVNEXTEFAK), the C-terminus is assigned correctly
and the incorrect sequence ending in Q is not a possi-
bility because the mass accuracy excludes Q from the
compositional analysis for y9. An example of how a
sequence is generated using LIPCUT peptide composi-
tion by residue mass for this specific example is shown
in Table 3. Starting from the C-terminal, residue masses
are added sequentially, but are shown in the alphabet-
ical format used internally by our algorithm. The ap-
proach used in this work employs multiple compari-
sons of experimentally measured masses with the
accurate theoretical masses in LIPCUT. It is these mul-
tiple determinations of mass that ultimately yields the
best assignment of sequences; for the example shown in
Table 3, the average error for use of K in the sequence is
16.2 mDa while the average error for use of Q is 28
mDa. The value of this approach is demonstrated more
extensively in the occurrence of several glutamines, as
in -galactosidase fragments 963-974 and 623-631,
which have triplicate tandem glutamines, the instance
of KQ degeneracy occurs only twice and once, respec-
tively.
The overall process by which sequences are gener-
ated is shown in Table 4a. The large number of y-ion
compositions within a 100 mDa band centered on the
measured m/z demonstrates this algorithm’s reliance on
previous peaks for the generation of a few unique
sequences; each rightward column-step represents one
more restriction on the amino acid compositions as they
11
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rightmost column for each row is always 1 because only
1 unique entry exists for any given combination.
While displaying a table for each inferior sequence
possibility would prove useless, Table 4b rendered with Q
instead of K, and shows how the algorithm differentiates
between K and Q. At m/z  1050.579, no compositions
exist that meet the criteria for extension of the AEEFNQTX
to AEEFNQTVX (the addition of V). This branch pro-
gresses as a missed fragmentation, yielding a final se-
quence possibility of X(VN)EXTEFAQ, but the score is
decreased due to the absence of the 1050.579 peak to
support it.
A comparison of our results to those obtained using
the only other software tailored to MALDI TOF/TOF
spectra, the ABI GPS DeNovo Explorer software pro-
vided with the instrument, was undertaken in an at-
tempt to validate our approach. The comparison dem-
onstrated several advantages to the use of the approach
presented here. The DeNovo Explorer generated correct
sequences for only ten of the twenty-two peptides.
More significantly however, when incorrect sequences
were produced, they generally had substantial, more
than three incorrect residues, regions of incorrect se-
quence. In the case of the b-gal 507-518, the DeNovo
Explorer software derived a completely incorrect se-
quence. The origin of these incorrect results is unclear;
manual validation of the fragmentation data could find
no support for the incorrect sequences.
Several recent papers [17, 24 –29] demonstrate
charge derivatization methods for peptides before
tandem mass spectrometric sequencing analysis. The
derivatizations promote peptide fragmentation in the
gas phase and/or simplify the spectrum by reducing
the number of fragmentation pathways. Two notable
examples [17, 29] also elucidate informatics methods
to analyze the simplified fragment spectra. While
charge derivatization may increase sensitivity, justi-
fication of the improvements on sequencing perfor-
mance would be helpful. Introduction of more heu-
ristics, such as the assumption that the modified
peptide will fragment to generate only y- or only
Table 3. Peak masses and theoretical residual masses for the y-
benefit of multiple independent error determinations in elucidati
impossible with a 50 mDa mass accuracy.
y Composition
Measured
Peak (m/z)
Obs’d Residual
Mass
Th
1 K 147.110 128.092
2 AK 218.152 199.134
3 AFK 365.201 346.183
4 AEFK 494.244 475.226
5 AEFKT 595.292 576.274
6 AEFKTX 708.379 689.361
7 AEEFKTX 837.416 818.398
8 AEEFKNTX 951.468 932.450
9 AEEFKNTVX 1050.579 1031.561
10 AEEFKNTVXX 1163.600 1144.582b-ions, into the spectral sequencing diminishes com-putational complexity and so run time, but the justi-
fication for these heuristics remains dubious, for the
spectral assignments often include supposedly for-
bidden ion types, and the mistaken assumption of ion
type can lead to undesirable sequence shunting. It
was shown in this paper that complete compositional
analysis, which is made rapid with LIPCUT, is able to
distinguish y- and b-ions. Further, it was found that
using the complementary ion types enriches sequence
confidence and elucidates some ambiguities resulting
from low mass accuracy.
Conclusions and Future Directions
The approach described here introduces a new basis for
peptide de novo sequencing. With this approach, the
peptide mass for which a complete and reliable de novo
sequence can be obtained is extended beyond m/z 1600.
In addition, the increased computational robustness
afforded by the use of the LIPCUT dataset allows for the
exploitation of composition enumeration within a mass
accuracy consistent with unimolecular decompositions
obtained in a MALDI tandem TOF instrument. Addi-
tional work will focus on two areas; (1) incorporation of
what is now the manual process of evaluating internal
ions, and (2) the use of MAARIAN with data obtained
from other instruments, and ions formed by electros-
pray ionization. This will require modifications to con-
sider multiple charge states in the spectrum. Of equal
interest is the potential application of LIPCUT and
MAARIAN to spectra involving electron capture disso-
ciation (ECD).
We also envision an equally viable extension of
MAARIAN to incorporate the ability to consider certain
post-translational or chemical modifications. Prelimi-
nary efforts suggest that such changes will only subtly
change the computational order and only modestly
increase overall computation time for each modification
considered. In addition to the LIPCUT database being
available upon request, all of the peak lists used in this
work are available in the Supplementary Material Sec-
of tryptic BSA fragment 66–75 (XVNEXTEFAK) shows the
e K/Q ambiguity even when correct determination is
t Residual
s with K
Error with
K (mDa)
Theoret Residual
Mass with Q
Error with
Q (mDa)
28.095 3 128.059 43
99.132 2 199.096 38
46.200 17 346.164 19
75.243 17 475.207 19
76.291 17 576.254 20
89.375 14 689.338 23
18.417 19 818.381 17
32.460 10 932.424 26
31.529 32 1031.492 69
44.613 31 1144.576 6series
ng th
eore
Mas
1
1
3
4
5
6
8
9
10tion (which can be found in the electronic version of this
Table 4. (a) Composition-based filtering of m/z 1163.600 using K
Measured
m/z
Total y-
compositions
Subset
containing
K
Subset
containing
AK
Subset
containing
AFK
Subset
containing
AEFK
Subset
containing
AEFKT
Subset
containing
AEFKTX
Subset
containing
AEEFKTX
Subset
containing
AEEFKNTX
Subset
containing
AEEFKNTVX
Subset
containing
AEEFKNTVXX
147.110 3 1
218.152 3 1 1
365.201 14 3 1 1
494.244 79 9 2 1 1
595.292 274 43 7 3 1 1
708.379 688 227 81 21 2 1 1
837.416 3377 1107 470 121 21 7 1 1
951.468 10707 3686 1701 416 102 33 8 2 1
1050.579 11440 6017 3037 949 171 60 24 4 1 1
1163.600 55906 26255 14289 3681 911 243 88 14 2 1 1
(b) Composition-based filtering of m/z 1163.600 using Q
Measured
m/z
Total y
compositions
Subset
containing
Q
Subset
containing
AQ
Subset
containing
AFQ
Subset
containing
AEFQ
Subset
containing
AEFQT
Subset
containing
AEFQTX
Subset
containing
AEEFQTX
Subset
containing
AEEFQNTX
Subset
containing
AEEFQNTVX
Subset
containing
AEEFQNTVXX
147.110 3 1
218.152 3 1 1
365.201 14 2 1 1
494.244 79 8 2 1 1
595.292 274 30 5 2 1 1
708.379 688 124 48 16 1 1 1
837.416 3377 810 354 113 16 7 1 1
951.468 10707 2906 1367 411 74 28 9 2 1
1050.579 11440 2947 1447 434 61 19 9 0 0 0
1163.600 55906 17947 9709 2846 605 176 88 12 1 1 1
1048
O
L
SO
N
E
T
A
L
.
J
A
m
Soc
M
ass
Sp
ectrom
2006,
17,
1041–1049
1049J Am Soc Mass Spectrom 2006, 17, 1041–1049 DE NOVO PEPTIDE SEQUENCING BY EXHAUSTIVE ENUMERATIONarticle); all spectra will be made available as ASCII files
upon request.
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